Pliant Therapeutics (PLRX) Other Accumulated Expenses (2021 - 2026)

Pliant Therapeutics (PLRX) has reported Other Accumulated Expenses for 6 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 71.21% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 71.21% YoY), while the FY2025 annual figure was $4.8 million, down 66.55% from the prior year.
• Other Accumulated Expenses eased to $4.1 million in Q1 2026 per PLRX's latest filing, from $4.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $23.0 million in Q3 2024 and bottomed at $4.1 million in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $13.2 million across 5 years, with a median of $14.0 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 91.17% — and 2026, when it slumped 71.21%.
• Pliant Therapeutics' Other Accumulated Expenses stood at $11.2 million in 2022, then gained by 11.04% to $12.5 million in 2023, then gained by 15.31% to $14.4 million in 2024, then slumped by 66.55% to $4.8 million in 2025, then dropped by 13.8% to $4.1 million in 2026.
• Business Quant data shows PLRX's Other Accumulated Expenses at $4.1 million in Q1 2026, $4.8 million in Q4 2025, and $7.8 million in Q3 2025.